No data to show
OTCM
GRTSQ
Market cap0kUSD
Apr 03, Last price
0.00USD
Name
Gritstone bio Inc
Chart & Performance
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
66.91%
Rev. gr., 5y
2.32%
Revenues
1m
-85.64%
Net income
-138m
L+22.42%
CFO
-122m
L+4.92%
Earnings
Aug 11, 2025
Profile
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 1,331 -85.64% | 9,269 -80.16% | ||||||
Cost of revenue | 155,965 | 156,064 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (154,634) | (146,795) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 7,423 | (6,560) | ||||||
Tax Rate | ||||||||
NOPAT | (162,057) | (140,235) | ||||||
Net income | (138,490) 22.42% | (113,127) 50.93% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 8,092 | 63,847 | ||||||
BB yield | -3.43% | -20.35% | ||||||
| Debt | ||||||||
Debt current | 13,808 | 5,294 | ||||||
Long-term debt | 155,598 | 55,989 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | 709 | 150 | ||||||
Net debt | 82,543 | (114,635) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (121,648) | (115,946) | ||||||
CAPEX | (4,572) | (5,872) | ||||||
Cash from investing activities | 102,341 | (12,964) | ||||||
Cash from financing activities | 25,117 | 83,098 | ||||||
FCF | (207,361) | (134,509) | ||||||
| Balance | ||||||||
Cash | 81,573 | 171,887 | ||||||
Long term investments | 5,290 | 4,031 | ||||||
Excess cash | 86,796 | 175,455 | ||||||
Stockholders' equity | (659,536) | (521,129) | ||||||
Invested Capital | 823,774 | 732,376 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 115,528 | 90,918 | ||||||
Price | 2.04 -40.87% | 3.45 -73.17% | ||||||
Market cap | 235,676 -24.86% | 313,668 -69.08% | ||||||
EV | 318,219 | 199,033 | ||||||
EBITDA | (147,043) | (140,235) | ||||||
EV/EBITDA | ||||||||
Interest | 4,036 | 1,235 | ||||||
Interest/NOPBT | ||||||||